ArticleOncogene2005
RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.Molecular cancer therapeutics · 2023Article
- Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway.Cancer biomarkers : section A of Disease markers · 2018Article
- Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma.Cell death & disease · 2018Article
- Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2.Oncotarget · 2017Article
- Attenuation of teratoma formation by p27 overexpression in induced pluripotent stem cells.Stem cell research & therapy · 2016Article
- Article
- Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration.Cell reports · 2015Article
- Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53.Digestive diseases and sciences · 2015Article
- Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma.Experimental & molecular medicine · 2014Article
- Role of E3 ubiquitin ligases in lung cancer.World journal of clinical oncology · 2013Article
- Skp2 deficiency inhibits chemical skin tumorigenesis independent of p27(Kip1) accumulation.The American journal of pathology · 2013Article
- Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Frontiers in oncology · 2012Article
- Impaired ovarian development and reduced fertility in female mice deficient in Skp2.Journal of anatomy · 2011Article
- SCF E3 ubiquitin ligases as anticancer targets.Current cancer drug targets · 2011Review
- A clinical overview of centrosome amplification in human cancers.International journal of biological sciences · 2011Review
- The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase.Journal of virology · 2010Article
- Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.Molecular biology reports · 2009Review
- Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.Molecular cancer research : MCR · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The S-phase kinase-associated protein-2 (SKP2) plays a key role in ubiquitin-mediated proteolysis, which results in the progression of cells from a quiescence to proliferative state. SKP2 is overexpressed in a variety of tumors. In this study, we used small interfering RNAs (siRNAs) to inhibit the SKP2 expression in lung cancer cells and thereby investigate the role of SKP2 in lung tumorigenesis. Three lung cancer cell lines were transfected with siRNAs targeted against SKP2. SKP2-siRNAs specifically and efficiently reduced the levels of the SKP2 protein by 90% 48 h after transfection in all cell lines. In the A549 and H1792 cells, p27 expression was increased and the increase was inversely proportional to the level of SKP2; cell proliferation was reduced to 12 and 28%, respectively; apoptosis was increased to 36 and 30%, respectively; 36 and 28% of cells accumulated in the sub-G1 phase, respectively; and the population of cells in the G1 phase was decreased to 37 and 41%, respectively. In addition, the SKP2-depleted A549 and H1792 cells showed decreased levels of cyclin E/CDK2. Correspondingly, only 4 and 6% of the treated A549 and H1792 cells had multiple centrosomes, respectively, compared with 43 and 46% of the control cells, respectively. These results imply that SKP2 plays an oncogenic role in lung cancer and that SKP2 silencing may be useful in the treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.